Clinical Trial Search

Primary: Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding…

Primary: Change in High-sensitivity C-reactive Protein — 0.72; -0.61 mg/dl

Primary: Number of Participants With 1 or More Severe Asthma Exacerbations — 186; 154 participants — p=0.036

Primary: Average Total Combined Rhinoconjunctivitis Daily Symptom Score (DSS) and Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire Grass Pollen Season (GPS)…

Primary: Time to Invasive Disease-free Survival (IDFS) Event — NA; NA Months — p=0.1810

Primary: Incidence of Ocular and Non-Ocular Adverse Events (AEs) — 10; 8 participants

Primary: Fasting Serum Triglycerides — -4.26; -25.94; -25.46; -30.86 Percent change from baseline — p=0.005

Primary: Change From Baseline to Endpoint in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Total Attention Deficit-Hyperactivity Disorder (ADHD) Symptoms…

Primary: Overall Survival (OS) — NA; 77 weeks — p=0.0017

Primary: Peak Anti-Xa Level — 0.35; 0.46; 0.57; 0.27 u/ml — p=0.4

Primary: Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24 — 0.341; 0.377 Liters — p=0.162

Primary: Cmax of Fentanyl — 0.67; 0.26 ng/mL

Primary: Percentage of Participants With at Least 1 Adverse Event — 38.2 Percentage of participants

Primary: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) — 240; 304 Subjects

Primary: Change From Baseline in the Weekly Itch Severity Score at Week 12 — -5.14; -5.87; -8.14; -9.77 Units on a scale — p=0.4637